Medical News
Addiction
Allergies
Alternative Medicine
Asthma
Cancer
Cardiology
Chiropractic
Dental
Dermatology
Diabetes
Emergency
Family Medicine
General
Geriatrics
Hospitals
Infectious Diseases
Internal Medicine
Managed Care / HMO
Medical Products
Mental Health
Neurology
Nursing
Nutrition
OB / GYN
Pediatrics
Pharmaceuticals
Physical Therapy
Plastic Surgery
Psychology
Radiology / Imaging
Research
Sports Medicine
Surgery
Vision

Hughes & Coleman File Suit Against MRI Dye Manufacturers

Dye used in MRIs allegedly results in serious injury.

Nashville, Tenn. (PRWEB) July 28, 2007 -- A lawsuit has been filed in the United States District Court, Middle District of Tennessee, Nashville Division (Case No. 3:07-0774), today on behalf of clients Jerry and Lynne Hensley against Tyco International, Ltd. (NYSE: TYC), because of serous injuries caused by an injectable dye used in magnetic resonance imaging (MRI) scans.

In 2004, Jerry Hensley, a kidney failure patient, underwent an enhanced MRI, which included injecting the drug OptiMARK, a gadolinium-based dye, used as a contrast agent. One week after the MRI, Hensley started showing signs of Nephrogenic Systemic Fibrosis (NSF). Hensley's symptoms included thickened skin around both elbows and both knees, pain in both legs, knees, and elbows along with trouble walking. The FDA has recalled gadolinium dyes stating:

"Patients with moderate to end-stage kidney disease who receive an MRI with a gadolinium-based contrast agent may get NSF, which is debilitating and may cause death."

The suit charges the defendants as knowing that the dye could cause NSF in kidney patients, but continued to distribute it. They also failed to warn physicians of the risks of kidney patients potentially developing NSF.

Hensley's attorney, Lee Coleman, co-founder of Hughes & Coleman, stated that, "Mr. Hensley had the right to be warned that because of his kidney disease, it was very risky for him to receive the injection of the dye (gadolinium) before he had his MRI. We believe we can prove that the defendants have known for years that kidney disease patients who receive the injection of gadolinium-based dye were at very high risks for developing NSF, which is a horrible medical condition. Unfortunately, the defendants chose to conceal the risk of the procedure, so Mr. Hensley's doctors could not warn him."

About Hughes & Coleman
Hughes & Coleman injury lawyers are committed to providing excellent, efficient legal services and achieving outstanding results in Kentucky and Tennessee. Their goal is to develop and maintain long-term, mutually beneficial attorney-client relationships. The professionals at Hughes & Coleman are well-known for their customer service and client satisfaction. Co-founders J. Marshall Hughes and Lee L. Coleman are both accomplished injury attorneys with strong ties to the community and are members of various civic and professional organizations.

###

Simillar Articles

CofmanTownsley Files a Lawsuit Against the Manufacturers of Special Dye Used for MRI Scans
MRI dye linked to highly toxic metal and potentially fatal skin disease.
Research May Predict Development of Kidney Failure in People with Type II Diabetes
An alumnus of the American Kidney Fund's Clinical Scientist in Nephrology program is conducting research that may one day help doctors predict which patients with type 2 diabetes will develop...
American Kidney Fund Launches Screening Program in New York City
The American Kidney Fund today announced the launch of its kidney disease education and screening program in New York City.
Cory Watson Crowder & DeGaris Files Lawsuit against Pharmaceutical Giant Bayer AG
Cory Watson Crowder & DeGaris, P.C., announced that it has filed a complaint against Bayer Corporation and its parent company, Bayer AG on behalf of plaintiff Ada M. Williams. Ms. Williams...
American Kidney Fund Unveils Results from First Large-Scale Survey on Impact of Medicare Part D...
Nearly 60 percent of patients with kidney failure have difficulty paying for medications while in the Medicare Part D coverage gap.
Home Terms of Use Privacy Policy Contact Us